This discovery corroborates similar findings in other hematological malignancies where BET proteins contribute to oncogenesis and immunosuppression (e.g., AML) (72) and supports BET-i as a useful component of treatment strategies in CLL to yield lasting anticancer control. The gene discussed is DNER; the disease is acute myeloid leukemia.